deoxycytidine has been researched along with rg 7128 in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 31 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alfredson, T; Brandl, M; Chow, J; Comstock, K; Li, F; Lin, F; Liu, Y; Sarma, K | 1 |
| Berrey, M; Cammack, N; De La Rosa, A; Ewing, A; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Seshaadri, A; Symonds, B; Yan, JM | 1 |
| Thomas, DL | 1 |
| Angus, PW; Baher, L; Berrey, MM; Bradford, W; Chu, T; Elston, R; Gane, EJ; Ipe, D; Laughlin, M; Lopatin, U; Morcos, PN; Najera, I; Ritchie, B; Roberts, SK; Shulman, NS; Smith, PF; Stedman, CA | 1 |
| Ghany, MG; Seeff, LB | 1 |
| Lawitz, EJ; Membreno, FE | 1 |
| Dahari, H; Guedj, J; Perelson, AS; Shudo, E; Smith, P | 1 |
| Angus, PW; Chu, TW; Elston, R; Gane, EJ; Germer, S; Iglesias, VA; Ipe, D; Kulkarni, R; Lopatin, U; Lu, XY; Ritchie, B; Roberts, SK; Shulman, NS; Smith, PF; Stedman, C | 1 |
| Jacobson, I; Najera, I; Pawlotsky, JM | 1 |
| Gao, M; Lin, K; Liu, Q; Villareal, VA; Yang, PL | 1 |
| Ali, S; Chhabra, M; Chin, DJ; Ilnicka, M; Kang, H; Klumpp, K; Kosaka, A; Le Pogam, S; Nájera, I; Shulman, NS; Smith, P; Yan, JM | 1 |
| Chatterjee, A; Perelson, AS; Smith, PF | 1 |
| Pockros, PJ | 1 |
| Bzowej, N; Chen, YC; Ferenci, P; Herring, R; Ipe, D; Jensen, D; Ma, MM; Munson, ML; Najera, I; Pockros, P; Rodriguez-Torres, M; Thommes, J; Vierling, J; Wedemeyer, H; Zeuzem, S | 1 |
| Chen, YC; Cooper, C; Dickson, R; Jensen, D; Kulkarni, R; Lou Munson, M; Najera, I; Pockros, PJ; Ramji, A; Taylor, R; Thommes, J; Tice, A; Tsai, N; Vierling, JM | 1 |
| Bukh, J; Gottwein, JM; Jensen, SB; Li, YP; Pedersen, J; Ramirez, S | 1 |
| Chen, YC; Goelzer, P; Haznedar, J; Moreira, S; Washington, C | 1 |
| Harrison, SA; Torres, DM | 1 |
| Baronas, V; Haines, K; Klumpp, K; Le Pogam, S; Li, L; Nájera, I; Piso, K; So, SS; Tong, X; Yan, JM | 1 |
| Fletcher, S; Hinojosa-Kirschenbaum, F; Inocencio, N; Javanbakht, H; Jiang, WR; Klumpp, K; Le Pogam, S; Ma, H; Nájera, I; Yan, JM | 1 |
| Ackrill, A; Badman, E; Bernaards, C; Chan, A; Chen, YC; Kulkarni, R; Moreira, S; Smith, PF; Thommes, J; Zhu, Y | 1 |
| Haines, K; Li, L; Najera, I; Tong, X | 1 |
| Chen, YC; Haznedar, J; Kulkarni, R; Lemenuel-Diot, A; Marbury, T; Moreira, S; Munson, ML; Robson, R; Smith, P; Smith, W; Thommes, JA; Washington, C | 1 |
| Ballester, R; Bernaards, C; Bertasso, A; Dwyer, C; Gane, EJ; Hammond, J; Kindrick, A; Marcellin, P; Morcos, PN; Nájera, I; Pockros, PJ; Shikhman, A; Shulman, NS; Smith, P; Stancic, S; Tong, X; Yetzer, ES; Zeuzem, S; Zhou, J | 1 |
| Brennan, B; Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF | 1 |
| Brunda, M; Chu, T; Elston, R; Gane, EJ; George, J; Glavini, K; Hammond, JM; Jensen, DM; Le Pogam, S; Nájera, I; Passe, S; Piekarska, A; Rodriguez, I; Zeuzem, S | 1 |
| Canini, L; Chatterjee, A; Guedj, J; Lemenuel-Diot, A; Perelson, AS; Smith, PF | 1 |
| Ahmadyar, S; Babusis, D; Barauskas, O; Feng, JY; McCutcheon, K; Park, Y; Perron, M; Perry, JK; Ray, AS; Sakowicz, R; Schultz, BE; Stepan, G; Xu, Y; Yu, H | 1 |
| Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H | 1 |
| Chen, YC; Haznedar, J; Kulkarni, R; Liu, M; Smith, P; Vistuer, C; Washington, C | 1 |
| Aron, G; Bushman, LR; Jimmerson, LC; Kiser, JJ; Koopmans, MPG; Mumtaz, N; Reusken, CBEM; van Kampen, JJA | 1 |
6 review(s) available for deoxycytidine and rg 7128
| Article | Year |
|---|---|
Management of untreated and nonresponder patients with chronic hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Biopsy; Decision Making; Deoxycytidine; Disease Management; Disease Progression; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Obesity; Polyethylene Glycols; Practice Patterns, Physicians'; Recombinant Proteins; Retreatment; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Virus Replication | 2010 |
The HCV NS5B nucleoside and non-nucleoside inhibitors.
Topics: Antiviral Agents; Clinical Trials as Topic; Deoxycytidine; Guanosine Monophosphate; Hepatitis C; Humans; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2011 |
Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase.
Topics: Antiviral Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; RNA-Dependent RNA Polymerase; Treatment Outcome | 2012 |
Anti-HCV drugs in the pipeline.
Topics: Animals; Antiviral Agents; Carbamates; Cyclosporine; Deoxycytidine; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Pyrrolidines; Valine; Virus Replication | 2011 |
Hepatitis C viral kinetics: the past, present, and future.
Topics: Antiviral Agents; Carbamates; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Imidazoles; Models, Biological; Oligopeptides; Protease Inhibitors; Pyrrolidines; Silybin; Silymarin; Valine | 2013 |
Nucleoside/nucleotide analogue polymerase inhibitors in development.
Topics: Cytidine; Deoxycytidine; Drugs, Investigational; Enzyme Inhibitors; Hepacivirus; Hepatitis C; Humans; Protein Conformation; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2013 |
17 trial(s) available for deoxycytidine and rg 7128
| Article | Year |
|---|---|
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Topics: Amino Acid Substitution; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; New Zealand; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Selection, Genetic; United States; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2010 |
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Topics: Administration, Oral; Adult; Antiviral Agents; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; RNA, Viral; Sulfonamides; Viral Nonstructural Proteins | 2010 |
Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Topics: Antiviral Agents; Deoxycytidine; Dideoxynucleotides; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Models, Theoretical; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.
Topics: Antiviral Agents; Australia; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Isoindoles; Kinetics; Lactams; Lactams, Macrocyclic; Models, Biological; Models, Statistical; New Zealand; Phenotype; Polymorphism, Single Nucleotide; Proline; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load; Virus Replication | 2012 |
Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Topics: Adult; Antiviral Agents; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Mutation; Placebos; Proline; RNA, Viral; Sulfonamides; Viral Load; Viral Nonstructural Proteins | 2012 |
PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Topics: Adolescent; Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2013 |
JUMP-C: a randomized trial of mericitabine plus pegylated interferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients.
Topics: Adolescent; Adult; Aged; Canada; Deoxycytidine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; United States; Young Adult | 2013 |
Single-dose pharmacokinetics of the HCV polymerase inhibitor mericitabine in healthy Caucasian and Japanese subjects.
Topics: Adult; Antiviral Agents; Area Under Curve; Asian People; Biotransformation; Deoxycytidine; Double-Blind Method; Drug Dosage Calculations; Enzyme Inhibitors; Female; Half-Life; Healthy Volunteers; Humans; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Tandem Mass Spectrometry; Viral Nonstructural Proteins; White People; Young Adult | 2014 |
In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
Topics: Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Mutation; Polyethylene Glycols; Recombinant Proteins; Replicon; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Base Sequence; Cyclopropanes; Deoxycytidine; DNA Replication; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Molecular Sequence Data; Mutation; Phenotype; Proline; RNA, Viral; Sequence Analysis, DNA; Sulfonamides; Viral Nonstructural Proteins | 2014 |
The effect of mild to moderate renal impairment on the pharmacokinetics of the nucleoside analog hepatitis C virus polymerase inhibitor mericitabine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Deoxycytidine; Female; Hepacivirus; Humans; Kidney Diseases; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Nucleosides; RNA-Dependent RNA Polymerase; Severity of Illness Index; Viral Nonstructural Proteins; Young Adult | 2014 |
Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study.
Topics: Adult; Aged; Cyclopropanes; Deoxycytidine; Electrocardiography; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides | 2015 |
A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.
Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Theoretical; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2015 |
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study.
Topics: Adult; Antiviral Agents; Australia; Benzothiadiazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Isoindoles; Lactams; Lactams, Macrocyclic; Male; Middle Aged; New Zealand; Phenotype; Proline; Quinolones; Remission Induction; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Viral Load | 2016 |
Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.
Topics: Antiviral Agents; Cyclopropanes; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Models, Biological; Proline; RNA, Viral; Sulfonamides; Viral Load | 2016 |
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Topics: Adult; Antibodies, Viral; Antimetabolites; Antiviral Agents; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
Evaluation of the effect of mericitabine at projected therapeutic and supratherapeutic doses on cardiac repolarization in healthy subjects: A thorough QT/QTc study.
Topics: Action Potentials; Administration, Oral; Adolescent; Adult; Antiviral Agents; Arrhythmias, Cardiac; Cross-Over Studies; Deoxycytidine; Double-Blind Method; Electrocardiography; Female; France; Healthy Volunteers; Heart Conduction System; Heart Rate; Hepacivirus; Humans; Male; Middle Aged; Protease Inhibitors; Risk Assessment; Viral Nonstructural Proteins; Young Adult | 2014 |
8 other study(ies) available for deoxycytidine and rg 7128
| Article | Year |
|---|---|
Isolation and identification of ester impurities in RG7128, an HCV polymerase inhibitor.
Topics: Antiviral Agents; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Contamination; Esters; Hepatitis C; Magnetic Resonance Spectroscopy; RNA-Dependent RNA Polymerase; Spectrometry, Mass, Electrospray Ionization | 2010 |
Curing hepatitis C with pills: a step toward global control.
Topics: Administration, Oral; Antiviral Agents; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Isoindoles; Lactams; Lactams, Macrocyclic; Proline; Sulfonamides; Viral Nonstructural Proteins | 2010 |
Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Chimera; Deoxycytidine; Genotype; Hepacivirus; Humans; Lead; Liver Neoplasms; Mutation; Peptide Hydrolases; Sofosbuvir; Transfection; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Small steps toward a better treatment for chronic hepatitis C infection: mericitabine, pegylated interferon, and ribavirin in the PROPEL and JUMP-C trials.
Topics: Deoxycytidine; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Ribavirin | 2013 |
Intracellular effects of the Hepatitis C virus nucleoside polymerase inhibitor RO5855 (Mericitabine Parent) and Ribavirin in combination.
Topics: Antiviral Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Combinations; Genotype; Hepacivirus; Humans; Ribavirin | 2014 |
Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.
Topics: Adult; Aged; Antiviral Agents; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2014 |
Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus.
Topics: Antiviral Agents; Cell Line; Deoxycytidine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA-Directed RNA Polymerases; Guanosine Monophosphate; Hepacivirus; Hepatitis C, Chronic; Humans; Mitochondria; Nucleosides; Oxygen Consumption; Protein Biosynthesis; RNA; RNA, Mitochondrial; Sofosbuvir; Transcription, Genetic; Virus Replication | 2016 |
Cell-line dependent antiviral activity of sofosbuvir against Zika virus.
Topics: A549 Cells; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; Deoxycytidine; Drug Repositioning; Flaviviridae; Humans; Inhibitory Concentration 50; Sofosbuvir; Vero Cells; Virus Replication; Zika Virus | 2017 |